Form 4: Apellis Pharmaceuticals CEO Cedric Francois Reports Stock Transactions

CEO Cedric Francois reports the sale of shares to cover tax withholding and the grant of restricted stock units.

Summary

• Cedric Francois, CEO of Apellis Pharmaceuticals, reported transactions involving the company's common stock.
• On January 17, 2025, he sold 6,007 shares at $29.9582 per share to cover tax withholding on restricted stock units.
• On January 21, 2025, he was granted 130,662 restricted stock units that vest 25% annually over four years.
• Francois also indirectly owns shares through several trusts, including The Cedric Francois Irrevocable Trust of 2023 2 (532,946 shares), The Cedric Francois Irrevocable Trust of 2023 (472,065 shares), The Francois Grossi Trust (300,000 shares), and The Francois-DuBois Educational Trust (234,411 shares).
• He disclaims beneficial ownership of shares held by these trusts except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The news is neutral. It reflects routine stock transactions by the CEO. The sale of shares is offset by the grant of restricted stock units.

Positives

• The grant of restricted stock units to the CEO aligns his interests with the long-term performance of the company.

Negatives

• The sale of shares by the CEO, even for tax purposes, could be perceived negatively by some investors.

Risks

• The vesting of restricted stock units is contingent upon continued service, creating a potential risk if the CEO were to leave the company.

Future Outlook

The restricted stock units vest over a four-year period, suggesting a commitment from the CEO to remain with the company.

Industry Context

Stock transactions by company executives are common and closely monitored by investors for insights into management's confidence in the company's future prospects.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholders, depending on market perception.

Key Dates